Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_1
1
17%
Ph phase_2
2
33%
Ph not_applicable
3
50%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
2(33.3%)
N/ANon-phased studies
3(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(1)
Terminated(1)
Other(4)

Detailed Status

unknown4
Completed1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (16.7%)
Phase 22 (33.3%)
N/A3 (50.0%)

Trials by Status

unknown467%
completed117%
withdrawn117%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD

NCT01016873
unknownphase_2

An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

NCT01521065
unknownnot_applicable

IRay to Treat Polypoidal Choroidal Vasculopathy (PCV) Secondary to Age-Related Macular Degeneration (AMD

NCT01516294
unknownnot_applicable

Iray for Vascularized Pigment Epithelial Detachment (VPED) Secondary to Age Related Macular Degeneration

NCT01521819
unknownphase_1

Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

NCT01217762
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT01016873Phase 2

INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD

Completed
NCT01521065Phase 2

An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Unknown
NCT01516294Not Applicable

IRay to Treat Polypoidal Choroidal Vasculopathy (PCV) Secondary to Age-Related Macular Degeneration (AMD

Unknown
NCT01521819Not Applicable

Iray for Vascularized Pigment Epithelial Detachment (VPED) Secondary to Age Related Macular Degeneration

Unknown
NCT01217762Phase 1

Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

Unknown
NCT01339949Not Applicable

Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
6